Biomarin Pharmaceutical (BMRN) EBIAT (2017 - 2025)
Biomarin Pharmaceutical (BMRN) has disclosed EBIAT for 16 consecutive years, with -$46.6 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT fell 137.28% year-over-year to -$46.6 million, compared with a TTM value of $348.9 million through Dec 2025, down 18.26%, and an annual FY2025 reading of $348.9 million, down 18.26% over the prior year.
- EBIAT was -$46.6 million for Q4 2025 at Biomarin Pharmaceutical, down from -$30.7 million in the prior quarter.
- Across five years, EBIAT topped out at $240.5 million in Q2 2025 and bottomed at -$57.9 million in Q4 2021.
- Average EBIAT over 5 years is $51.0 million, with a median of $34.0 million recorded in 2022.
- The sharpest move saw EBIAT plummeted 440.02% in 2021, then skyrocketed 8282.73% in 2023.
- Year by year, EBIAT stood at -$57.9 million in 2021, then soared by 99.57% to -$249000.0 in 2022, then surged by 8282.73% to $20.4 million in 2023, then soared by 513.22% to $124.9 million in 2024, then tumbled by 137.28% to -$46.6 million in 2025.
- Business Quant data shows EBIAT for BMRN at -$46.6 million in Q4 2025, -$30.7 million in Q3 2025, and $240.5 million in Q2 2025.